Moderna Again Faces Claims It Excluded Others’ Work In Developing COVID-19 Vaccine

 
• By Brenda Sandburg

Arbutus Biopharma alleges Moderna refused to license patents covering its lipid nanoparticle delivery platform in developing Spikevax. Moderna says it created its own proprietary LNP delivery technology.

Lipid nanoparticles
Arbutus claims Moderna used its patented lipid nanoparticle technology to develop Spikevax • Source: Alamy

More from Vaccines

More from Pink Sheet